Mr. DiLeo joined Anokion in 2018 to lead its then corporate alliance with Celgene (later BMS) and advance preclinical programs toward IND. Shortly after joining, Mr. DiLeo was named program lead for ANK-700 in multiple sclerosis leading the program to delivery of key milestones in 2019 and following a successful IND submission in 2020. Mr. DiLeo brings over 20 years of product development and operations experience to Anokion leading technical programs and external relationships across a variety of products and therapeutic areas. Prior to joining Anokion, Mr. DiLeo spent over 11 years at Dyax Corp. in a variety of roles, ultimately being named program manager for the landelumab antibody program in HAE, where he participated in the program’s eventual sale to Shire plc and into Phase 3. Prior to joining Anokion, Mr. DiLeo led commercial manufacturing efforts and launch-related supply activities at TESARO. Mr. DiLeo spent his early career at Biogen and Millipore Corporation.

Mr. DiLeo holds B.S. and M.S. degrees in Chemical Engineering as well as an M.B.A. all from Rensselaer Polytechnic Institute.